Experts Video Reports: Gastrointestinal Cancers track

Reporting from ASCO 2022 Annual Meeting in Chicago, Chiara Cremolini puts into context presented research on panitumumab first-line therapy in RAS wild-type metastatic Colorectal Cancer. She details the results from the PARADIGM trial testing chemotherapy plus panitumumab vs chemotherapy plus bevacizumab, evidence from the TRIPLETE trial on the benefit of chemotherapy intensification with panitumumab, and findings from the IMPROVE study testing intermittent vs continuous panitumumab plus chemotherapy in this setting.

Reporting from the ESMO Congress 2021, Elizabeth Smyth comments on the updated results from the CheckMate 649 in advanced gastric, GEJ and oesophageal cancer that confirm chemotherapy + nivolumab as a new standard of care, while the new results of the immunotherapy combination arm show a possible benefit for subgroups of patients only. She further discusses the encouraging results from second line treatment with trastuzumab deruxtecan in patients with HER2-positive gastric cancer. Finally, she explains the encouraging results of the CLDN 18.2-targeted CAR-T cell therapy in digestive cancers.

Reporting from the ESMO Congress 2021, Filippo Pietrantonio discusses the results from the FOCUS4-C trial on adavosertib in TP53 and RAS mutant metastatic colorectal cancer patients. He also covers results from the MAYA trial investigating strategies based on molecular selection and hypermutation induction to turn microsatellite stable metastatic colorectal cancer sensitive to immunotherapy.

Reporting from 2021 ASCO Annual Meeting, Ian Chau reports on practice changing results of immunotherapy in gastric and oesophageal cancers. He comments first on CheckMate 648 testing nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy in advanced oesophageal squamous cell carcinoma, then on CheckMate 649 evaluating the benefits of adding nivolumab to first-line chemotherapy in advanced gastroesophageal cancer. Finally he discusses the efficacy and safety results from CheckMate 577 testing adjuvant nivolumab following neo-adjuvant chemoradiotherapy in resected oesophageal or gastroesophageal junction cancer.

Reporting from the ESMO Virtual Congress 2020, Yelena Janjigian comments on practice changing results with first-line immune checkpoint inhibitor plus chemotherapy in advanced gastric, gastro-oesophageal junction or oesophageal cancers. She details results that are both, clinically meaningful and statistically significant in terms of progression-free and overall survival, while there were no new signals regarding tolerance.

Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Konstantinos Kamposioras comments on practice changing results from colorectal cancer trials.

Reporting from ESMO 2019 Congress, Florian Lordick comments on results from the ATTRACTION-3 positive study with immune checkpoint inhibitor in second-line treatment for metastatic oesophageal squamous cancer that show clinically relevant benefit, although it is necessary to see if the results will translate also into non-Asian populations. He also discusses 2 presentations from the KEYNOTE-062 study with non-inferior health-related quality-of-life data and a biomarker analysis in first-line treatment for advanced gastric cancer - while no benefit was observed with immunotherapy alone in the overall study population, there was a clear benefit in patients with MSI-high tumours which justifies upfront testing and a specific treatment approach.

A. Lamarca reports on study results presented on pancreatobiliary cancers at ASCO 2019.